New Topical Pharma & Biotech Company Reports by MP Advisors Now Available at MarketPublishers.com
14 Sep 2012 • by Natalie Aster
LONDON - Market Publishers Ltd informs that new in-demand MP Advisors reports on various pharma & biotech companies have been added to its catalogue.
These most recently published reports take an up-close look at the new drug R&D pipeline of various pharmaceutical and biotechnology companies worldwide in terms of generated revenue. The reports examine the financial performance of the company under consideration, capture key market issues and trends, extracting sales for the products covered and providing estimates and forecasts of the global biopharma market, and a lot more.
New Company Reports List Incorporates:
- Vertex - INCIVEK’s Life Extension by ALS-2200?
- Roche - AVAglio Study Positive: PFS Endpoint Met in Glioblastoma
- Onyx pharma - In the Driver’s Seat, with Kyprolis Approval
- Medivir AB - “Simeprevir in the HCV Race - Value Un-Appreciated”
- IPCA - Better Visibility of Sales and Margin Growth
- Eli-Lilly- Solanezumab - A Dead or Alive trump card? Does Positive Trend in Mild Alzheimer’s Patients Supports an Approval?
- DISHMAN - A Bounce Back - Though Still Away From the Turning Point
- Celgene - Waiting for More Positives...
- Alexion - Innovative Drugs for Orphan Diseases = Driving Expectations and Valuations!
- SUN PHARMA - At a Sweet Spot
- Pfizer- Bapineuzumab IV Discontinuation cuts Speculation value in PFE price
- ERS 2012 Preview: QVA-149-LABA/LAMA FDC well Positioned to Take a Share in the Second Line and Third Line Setting for Treatment of COPD
More new company reports and other studies by the publisher can be found at MP Advisors page.